Results 41 to 50 of about 37,305 (235)

Myocarditis During Lenalidomide Therapy

, 2010
Objective: To report the first case of pathologically confirmed myocarditis in a patient receiving treatment with lenalidomide for non-Hodgkin's lymphoma. Case Summary: An 85-year-old woman with recurrent follicular lymphoma was treated with lenalidomide
Sunita Nasta, Mark Stonecypher, Stephen J Schuster, Joseph R Carver, Elise A Chong, James E Wheeler, Tahamtan Ahmadi   +6 more
core   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. [PDF]

, 2015
Background High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly diagnosed myeloma.
OMEDE', P., RIA, R., SPADA, S., PETRO', D., EVANGELISTA, A., CATALANO, L., CORRADINI, P., MALFITANO, A., HAJEK, R., CAMPBELL, P., SPENCER, A., GAY, F, PETRUCCI, M. T., CONTICELLO, C., CARELLA, A., PALUMBO, A., MAGAROTTO, V., OLIVA, S., PESCOSTA, N., OFFIDANI, M., LIBERATI, A. M., PATRIARCA, Francesca, PULINI, S., BOCCADORO, M., SINISCALCHI, A., POUR, L.   +25 more
core   +3 more sources

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Advanced Science
First‐line treatment of multiple myeloma, a prevalent blood cancer lacking a cure, using anti‐CD38 daratumumab antibody and lenalidomide is often inadequate due to relapse and severe side effects.
Yueh‐Hsiang Yu, Wei‐Ting Tian, Cédric Grauffel, Wei‐Chen Lin, Ming‐Yu Hsieh, Pei‐Wen Wu, Hui‐Ju Lee, Chi‐Jiun Peng, Pei‐Hsuan Lin, Hsing‐Mao Chu, Carmay Lim, Tse Wen Chang   +11 more
doaj   +1 more source

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia

Haematologica, 2018
Therapy of acute myeloid leukemia in older persons is associated with poor outcomes because of intolerance to intensive therapy, resistant disease and co-morbidities.
Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, CL Beach, Ravi Vij, Xiwei Wang, Jim Zhong, Robert Peter Gale   +12 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide

Blood Cancer Journal
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance ...
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K. Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A. Gertz, Wilson I. Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis, Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma M. Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar   +20 more
doaj   +1 more source

Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge

Case Reports in Oncology, 2014
Background: The introduction of the immunomodulatory drug lenalidomide has revolutionized the treatment of patients with myelodysplastic syndromes (MDS) and deletion of the long arm of chromosome 5.
Francesco Pisani, Giulia Orlandi, Roberta Merola   +2 more
doaj   +1 more source

Acute Liver Rejection in a Multiple Myeloma Patient Treated with Lenalidomide

Case Reports in Transplantation, 2020
Herein we present a patient that underwent a liver transplant due to primary biliary cholangitis (PBC) and after 9 years developed multiple myeloma. Following the cessation of mycophenolate mofetil and 2 weeks after lenalidomide treatment was started ...
Iuliana Vaxman, John Eaton, Hee Eun Lee, Morie A. Gertz   +3 more
doaj   +1 more source

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

, 2011
Item does not contain fulltextThis phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System Low-/Intermediate-1-risk ...
Boekhorst, Peter A. W. te, Fu, T, Platzbecker, Uwe, Guerci-Bresler, A, Uwe Platzbecker, Beyne-Rauzy, Odile, Carlo Aul, Selleslag, Dominik, Muus P, Del Canizo, C., Tommy Fu, Sanz, Guillermo, del Canizo, C, Consuelo del Cañizo, Quesnel B, Francis, J., Boekhorst, Peter Te, Aristoteles Giagounidis, Sanz, G, Platzbecker, U, Mufti, Ghulam, Bowen, D, null null, Moshe Mittelman, Nilsson, Lars, Petra Muus, Quesnel, B, te Boekhorst, Peter, Aul, C, Fu, Tommy, Lund University., Cazzola, M., Mufti G, Fu T, Lubbert, M, Selleslag, D., Mufti, G., Guerci-Bresler, Agnes, Mittelman M, Nilsson, Lars,, Nilsson, L., Sanz, G., Fenaux, Pierre, Agnes Guerci-Bresler, Sanz G, Luebbert, Michael, Peter te Boekhorst, Fenaux P, Lars Nilsson, Dominik Selleslag, Aul, Carlo, Schlegelberger B, Platzbecker U, Knight, R., Mittelman, M, del Canizo, Consuelo, Hellstrom-Lindberg, E., Knight, Robert, Aul C, Knight R, Platzbecker, U., Mufti, G, Lübbert, Michael, Aul, C., Hellström Lindberg E, Eva Hellström-Lindberg, Francis, J, Boekhorst, P. Te, Guerci Bresler A, Knight, R, Hellstrom-Lindberg, E, Beyne-Rauzy, O., Ganser, A., Schlegelberger, Brigitte, Arnold Ganser, MDS 004 Lenalidomide del5q Study Group, Brigitte Schlegelberger, Giagounidis, A, Schlegelberger, B, Beyne-Rauzy, O, Ganser, A, Mittelman, Moshe, Lubbert, M., Odile Beyne-Rauzy, Ganser A, Francis J, Hellstrom-Lindberg, Eva, Fenaux, P., ?, ?, Bowen D, Pierre Fenaux, Selleslag D, Muus, P, Muus, P., Michael Lübbert, Quesnel, Bruno, Nilsson L, Nilsson, L, Fu, T., Cazzola, M, Del Cañizo C, Bruno Quesnel, Giagounidis A, Mittelman, M., Schlegelberger, B., Francis, John, Mario Cazzola, Giagounidis, A., Muus, Petra, Beyne Rauzy O, Bowen, David, Te Boekhorst P, Selleslag, D, David Bowen, Giagounidis, Aristoteles, Quesnel, B., Robert Knight, Ganser, Arnold, Guillermo Sanz, Guerci-Bresler, A., Fenaux, P, Cazzola, Mario, Ghulam Mufti, John Francis, Lübbert M, Bowen, D.   +125 more
core   +1 more source